JP2015510888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510888A5 JP2015510888A5 JP2014561175A JP2014561175A JP2015510888A5 JP 2015510888 A5 JP2015510888 A5 JP 2015510888A5 JP 2014561175 A JP2014561175 A JP 2014561175A JP 2014561175 A JP2014561175 A JP 2014561175A JP 2015510888 A5 JP2015510888 A5 JP 2015510888A5
- Authority
- JP
- Japan
- Prior art keywords
- unit dose
- item
- leucine
- vitamin
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 20
- 230000037149 energy metabolism Effects 0.000 claims description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 10
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 10
- 239000011726 vitamin B6 Substances 0.000 claims description 10
- 235000019158 vitamin B6 Nutrition 0.000 claims description 10
- 229940011671 vitamin b6 Drugs 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims 2
- 150000002614 leucines Chemical class 0.000 claims 2
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- LVRFTAZAXQPQHI-UHFFFAOYSA-N alpha-hydroxyisocaproic acid Natural products CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 claims 1
- ZFAVADMJZHASIM-UHFFFAOYSA-N hydroxymethyl butanoate Chemical compound CCCC(=O)OCO ZFAVADMJZHASIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 45
- 230000001965 increasing effect Effects 0.000 description 11
- 210000001789 adipocyte Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000000344 Sirtuin 1 Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608595P | 2012-03-08 | 2012-03-08 | |
| US61/608,595 | 2012-03-08 | ||
| US201261656407P | 2012-06-06 | 2012-06-06 | |
| US61/656,407 | 2012-06-06 | ||
| US13/662,345 | 2012-10-26 | ||
| US13/662,345 US9198454B2 (en) | 2012-03-08 | 2012-10-26 | Compositions, methods, and kits for regulating energy metabolism |
| PCT/US2013/030044 WO2013134736A1 (en) | 2012-03-08 | 2013-03-08 | Compositions, methods, and kits for regulating energy metabolism |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017171209A Division JP2018012722A (ja) | 2012-03-08 | 2017-09-06 | エネルギー代謝を調節するための組成物、方法およびキット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510888A JP2015510888A (ja) | 2015-04-13 |
| JP2015510888A5 true JP2015510888A5 (enExample) | 2016-04-28 |
| JP6210517B2 JP6210517B2 (ja) | 2017-10-11 |
Family
ID=49114651
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561175A Expired - Fee Related JP6210517B2 (ja) | 2012-03-08 | 2013-03-08 | エネルギー代謝を調節するための組成物、方法およびキット |
| JP2017171209A Pending JP2018012722A (ja) | 2012-03-08 | 2017-09-06 | エネルギー代謝を調節するための組成物、方法およびキット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017171209A Pending JP2018012722A (ja) | 2012-03-08 | 2017-09-06 | エネルギー代謝を調節するための組成物、方法およびキット |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9198454B2 (enExample) |
| EP (1) | EP2822579B1 (enExample) |
| JP (2) | JP6210517B2 (enExample) |
| AU (2) | AU2013229779B2 (enExample) |
| CA (1) | CA2866718C (enExample) |
| HK (1) | HK1205942A1 (enExample) |
| WO (1) | WO2013134736A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12014500198A1 (en) | 2011-07-15 | 2017-02-10 | Nusirt Sciences Inc | Compositions and methods for modulating metabolic pathways |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| JP6469015B2 (ja) | 2012-11-13 | 2019-02-13 | ニューサート サイエンシーズ， インコーポレイテッド | エネルギー代謝を増大させるための組成物および方法 |
| US9585876B2 (en) | 2013-03-15 | 2017-03-07 | Nusirt Sciences, Inc. | Leucine and nicotinic acid reduces lipid levels |
| JP2017506651A (ja) | 2014-02-27 | 2017-03-09 | ニューサート サイエンシーズ， インコーポレイテッド | 脂肪肝の低減または予防のための組成物および方法 |
| US20180235917A1 (en) * | 2014-09-24 | 2018-08-23 | Nusirt Sciences, Inc. | Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia |
| WO2017040407A1 (en) * | 2015-09-01 | 2017-03-09 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash) |
| WO2017073729A1 (ja) * | 2015-10-30 | 2017-05-04 | 恭正 加藤 | 糖尿病治療用組成物 |
| US11701336B2 (en) | 2015-10-30 | 2023-07-18 | Yasumasa Kato | Method of determining composition effective for treating diabetes |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| IT201700087376A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| US10682325B2 (en) | 2017-08-14 | 2020-06-16 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
| JP2021527670A (ja) | 2018-06-20 | 2021-10-14 | アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． | 筋肉中の脂肪浸潤の治療のための組成物及び方法 |
| IT201800006725A1 (it) | 2018-06-27 | 2019-12-27 | Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche | |
| US10568352B1 (en) | 2018-10-25 | 2020-02-25 | Wiser Concepts, LLC | Nutritional compositions and methods of treatment therewith |
| IT201900002109A1 (it) | 2019-02-13 | 2020-08-13 | Professional Dietetics Spa | Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale |
| IT202000000442A1 (it) | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
| JP7795755B2 (ja) * | 2020-04-17 | 2026-01-08 | 共栄化学工業株式会社 | 皮膚外用剤 |
| CN112056272A (zh) * | 2020-09-16 | 2020-12-11 | 华中农业大学 | 一种评价甜味剂摄入对小鼠影响的方法 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| KR20250159205A (ko) * | 2023-03-03 | 2025-11-10 | 그래즈 이노베이션 | 지방산의 강화된 대사성 산화를 위한 조성물 |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3810994A (en) | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
| DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| US4769027A (en) | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5087624A (en) | 1989-03-21 | 1992-02-11 | Nutrition 21 | Chromic picolinate treatment |
| US5886012A (en) | 1989-03-22 | 1999-03-23 | Peter K. T. Pang | Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers |
| US4992470A (en) | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US6764697B1 (en) | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
| US5419283A (en) | 1992-04-08 | 1995-05-30 | Ciuffo Gatto S.R.L. | Animal chew toy of starch material and degradable ethylene copolymer |
| JP3219838B2 (ja) | 1992-05-12 | 2001-10-15 | 沖電気工業株式会社 | 半導体素子の製造方法 |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| LU88369A1 (fr) | 1993-07-12 | 1994-04-01 | Michel Urso Prof Medecin Et Ch | Acides aminés à chaînes ramifiées |
| US5339771A (en) | 1993-09-15 | 1994-08-23 | Axelrod Herbert R | Animal chew toy containing animal meal |
| US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
| US5616569A (en) | 1994-03-28 | 1997-04-01 | The Iams Company | Pet food product containing fermentable fibers and process for treating gastrointestinal disorders |
| US6048903A (en) | 1994-05-03 | 2000-04-11 | Robert Toppo | Treatment for blood cholesterol with trans-resveratrol |
| EP0873754B1 (en) | 1996-01-09 | 2003-07-30 | Riken | Amino acid compositions |
| US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| IT1291113B1 (it) | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
| MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
| GB9723059D0 (en) | 1997-10-31 | 1998-01-07 | Mars Uk Ltd | Pet food |
| IL139376A0 (en) | 1998-05-04 | 2001-11-25 | Monomeric, oligomeric and polymeric knoevenagel condensation products | |
| US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| MXPA01006108A (es) | 1998-12-17 | 2002-09-18 | Alza Corp | Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos. |
| US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| ES2250112T3 (es) | 1999-03-08 | 2006-04-16 | Medicure Inc. | Analogos de piridoxal para el tratamiento de trastornos causados por carencia de vitamina b6. |
| FR2790645B1 (fr) | 1999-03-12 | 2001-06-08 | Arkopharma Laboratoires | Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols |
| WO2001021165A1 (en) | 1999-09-21 | 2001-03-29 | Rutgers, The State University | Resveratrol analogs for prevention of disease |
| US6527711B1 (en) | 1999-10-18 | 2003-03-04 | Bodymedia, Inc. | Wearable human physiological data sensors and reporting system therefor |
| US6280779B1 (en) | 1999-12-28 | 2001-08-28 | Colgate-Palmolive Company | Pet food for maintaining normal bowel health |
| US7261690B2 (en) | 2000-06-16 | 2007-08-28 | Bodymedia, Inc. | Apparatus for monitoring health, wellness and fitness |
| US6605038B1 (en) | 2000-06-16 | 2003-08-12 | Bodymedia, Inc. | System for monitoring health, wellness and fitness |
| EP1662989B1 (en) | 2000-06-16 | 2014-09-03 | BodyMedia, Inc. | System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability |
| US7689437B1 (en) | 2000-06-16 | 2010-03-30 | Bodymedia, Inc. | System for monitoring health, wellness and fitness |
| US6384087B1 (en) | 2000-09-01 | 2002-05-07 | University Of Tennesseee Research Corporation, Inc. | Materials and methods for the treatment or prevention of obesity |
| DE60039726D1 (de) | 2000-12-29 | 2008-09-11 | Martin Francis Gannon | Tiernahrungsmittelzusammensetzung |
| JP2004519241A (ja) | 2001-03-09 | 2004-07-02 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | 高齢化に伴う生理的障害を改善し寿命を延ばす組成物 |
| US6338862B1 (en) | 2001-03-26 | 2002-01-15 | Sarfaraz K Niazi | Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors |
| US6595929B2 (en) | 2001-03-30 | 2003-07-22 | Bodymedia, Inc. | System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow |
| EP1525323B1 (en) | 2001-11-09 | 2015-01-21 | Dana-Farber Cancer Institute, Inc. | Pgc-1beta, a novel pgc-1 homologue and uses therefor |
| US20030187055A1 (en) | 2002-02-25 | 2003-10-02 | Riker Donald K. | Synergistic pharmaceutical combinations for treating obesity |
| JP4545584B2 (ja) | 2002-05-17 | 2010-09-15 | デューク ユニバーシティ | 肥満を治療するための方法 |
| US6939556B2 (en) | 2002-06-26 | 2005-09-06 | Alza Corporation | Minimally compliant, volume efficient piston for osmotic drug delivery systems |
| FR2841784B1 (fr) | 2002-07-08 | 2007-03-02 | Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations | |
| US7020508B2 (en) | 2002-08-22 | 2006-03-28 | Bodymedia, Inc. | Apparatus for detecting human physiological and contextual information |
| CA2501899C (en) | 2002-10-09 | 2010-06-01 | Bodymedia, Inc. | Apparatus for detecting, receiving, deriving and displaying human physiological and contextual information |
| US20050064070A1 (en) | 2002-10-11 | 2005-03-24 | Jeffrey Liebrecht | Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same |
| US7744930B2 (en) * | 2002-11-22 | 2010-06-29 | Shaklee Corporation | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass |
| US20040254357A1 (en) | 2002-12-19 | 2004-12-16 | Zaloga Gary P. | Fatty acid phenolic conjugates |
| US7288570B2 (en) * | 2002-12-20 | 2007-10-30 | Nutricia N.V. | Stimulation of in vivo production of proteins |
| US20040120983A1 (en) | 2002-12-23 | 2004-06-24 | Philip Connolly | Nutritional supplement |
| WO2004083287A1 (en) | 2003-03-13 | 2004-09-30 | Vector Usa Inc. | A film having a liquid absorbed therein |
| US20040186046A1 (en) | 2003-03-17 | 2004-09-23 | Pfizer Inc | Treatment of type 1 diabetes with PDE5 inhibitors |
| NZ541516A (en) | 2003-03-18 | 2008-05-30 | Novartis Ag | Compositions comprising fatty acids and amino acids |
| US7160565B2 (en) | 2003-03-31 | 2007-01-09 | Breakthru Products, Llc | Hydration beverage and method of delivering nutrients |
| DE602004012745T2 (de) | 2003-05-14 | 2009-04-09 | Indus Biotech Pvt. Ltd. | Synergistische zusammensetzung zur behandlung von diabetes mellitus |
| WO2005003766A2 (en) | 2003-06-13 | 2005-01-13 | Whitehead Institute For Biomedical Research | Methods of regulating metabolism and mitochondrial function |
| EP1875816A3 (en) | 2003-07-10 | 2008-03-12 | Carl A. Forest | Beverages with specialized supplements |
| JP2005097273A (ja) * | 2003-08-19 | 2005-04-14 | Toyo Shinyaku:Kk | 運動能力向上組成物 |
| WO2005027720A2 (en) | 2003-09-12 | 2005-03-31 | Bodymedia, Inc. | Method and apparatus for measuring heart related parameters |
| WO2005049618A1 (en) | 2003-11-19 | 2005-06-02 | Dsm Ip Assets B.V. | Manufacture of vitamin b6 |
| EP1685833A1 (en) | 2003-11-21 | 2006-08-02 | Ajinomoto Co., Inc. | Remedy for diabetes |
| DK1694137T3 (da) | 2003-11-26 | 2009-04-27 | Hills Pet Nutrition Inc | Fremgangsm de til at reducere lugt af aff ring fra k ledyr |
| US8388949B2 (en) * | 2003-12-24 | 2013-03-05 | N.V. Nutricia | Compositions comprising pantothenic acid and their use for stimulating appetite |
| JP2007527418A (ja) | 2003-12-29 | 2007-09-27 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 肥満及びインシュリン耐性障害を治療又は防止するための組成物 |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US20050215882A1 (en) | 2004-03-23 | 2005-09-29 | The Regents Of The University Of Michigan | Noninvasive method to determine fat content of tissues using MRI |
| US8039009B2 (en) | 2004-06-17 | 2011-10-18 | Forest Laboratories Holdings Limited | Modified release formulations of memantine oral dosage forms |
| EP1762234A4 (en) | 2004-06-28 | 2010-05-05 | Kao Corp | AMPK AKTIVATOR |
| JP5070052B2 (ja) | 2004-08-17 | 2012-11-07 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法 |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US20080004335A1 (en) | 2004-11-29 | 2008-01-03 | Kinya Takagaki | Athletic Ability Enhancing Composition |
| US20060115555A1 (en) | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplements containing xanthone extracts |
| EP1853610A1 (en) | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| US20070014833A1 (en) | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| CA2607600A1 (en) | 2005-06-16 | 2006-12-28 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| CA2618370A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| WO2007041643A1 (en) | 2005-10-03 | 2007-04-12 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
| JP2007161675A (ja) * | 2005-12-16 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 疲労改善内服剤 |
| RU2421017C2 (ru) | 2006-01-10 | 2011-06-20 | Хилл'С Пет Ньютришн, Инк. | Композиции и способы, стимулирующие потерю жировой массы |
| EP1996215A2 (en) | 2006-02-28 | 2008-12-03 | Trustees Of Boston University | Metabolic regulators and uses thereof |
| US7691388B2 (en) | 2006-03-24 | 2010-04-06 | Ocean Nutrition Canada Limited | Compositions comprising Porphyra and methods of making and using thereof |
| JP2009532041A (ja) | 2006-04-05 | 2009-09-10 | ケマファー インコーポレーテッド | 食品栄養補助剤及びその使用 |
| JP2007306851A (ja) * | 2006-05-18 | 2007-11-29 | 仁 ▲吉▼井 | 食塩組成物およびその製造方法 |
| US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
| US20090291958A1 (en) | 2006-06-08 | 2009-11-26 | Auspex Pharmaceuticals, Inc. | Substituted PDE5 inhibitors |
| EA024161B1 (ru) | 2006-07-12 | 2016-08-31 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Фармацевтические композиции, содержащие замещенные ациланилиды |
| JP2008063328A (ja) | 2006-08-07 | 2008-03-21 | Kowa Co | 糸球体疾患治療剤 |
| JP5507802B2 (ja) | 2006-08-10 | 2014-05-28 | 花王株式会社 | 筋肉老化抑制剤 |
| JP2010514804A (ja) | 2006-12-29 | 2010-05-06 | ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ | 運動能力を高めるための方法 |
| CN101631859B (zh) | 2007-01-16 | 2017-10-13 | Ipintl有限责任公司 | 用于治疗代谢综合征的新组合物 |
| US20080319786A1 (en) | 2007-02-16 | 2008-12-25 | Stivoric John M | Publishing and insurance applications of lifeotypes |
| AU2007347422B2 (en) | 2007-02-23 | 2011-05-26 | Hill's Pet Nutrition, Inc. | Compositions and methods for controlling the weight of animals |
| US20080233245A1 (en) * | 2007-03-19 | 2008-09-25 | Lesley Joan White | Liquid nutrient composition for improving performance |
| US20080233244A1 (en) | 2007-03-23 | 2008-09-25 | Solae, Llc | Animal food compositions and treats |
| WO2008119070A1 (en) | 2007-03-28 | 2008-10-02 | Trustees Of Boston University | Methods of treatment using sirt modulators and compositions containing sirt1 modulators |
| US20080268038A1 (en) * | 2007-04-26 | 2008-10-30 | Wolfe Robert R | Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength |
| JPWO2008143182A1 (ja) | 2007-05-17 | 2010-08-05 | 株式会社カネカ | 甘草ポリフェノールを含有する組成物 |
| US20100204204A1 (en) | 2007-06-06 | 2010-08-12 | University Of South Florida | Nutraceutical co-crystal compositions |
| US20090054450A1 (en) | 2007-06-19 | 2009-02-26 | Ironwood Pharmaceuticals, Inc. | Compositions and methods of use for treating or preventing lipid related disorders |
| CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
| US7989007B2 (en) | 2007-07-03 | 2011-08-02 | Vincent James Enterprises, Llc | Weight loss composition |
| WO2009033034A1 (en) | 2007-09-07 | 2009-03-12 | Nike, Inc. | Wearable device assembly having athletic functionality |
| WO2009054994A2 (en) | 2007-10-23 | 2009-04-30 | President And Fellows Of Harvard College | Sirt-3 related methods and compositions for mimicking exercise |
| US20090156648A1 (en) | 2007-12-12 | 2009-06-18 | Iovate T. & P. Inc. | Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA) |
| CN101959404B (zh) | 2008-02-04 | 2015-12-02 | 墨丘瑞医疗有限公司 | 单磷酸腺苷活化蛋白激酶调节剂 |
| WO2009111472A2 (en) | 2008-03-03 | 2009-09-11 | Nike, Inc. | Interactive athletic equipment system |
| EP2265341A1 (en) | 2008-04-02 | 2010-12-29 | Nike International Ltd. | Wearable device assembly having athletic functionality |
| GB0809665D0 (en) | 2008-05-28 | 2008-07-02 | Mars Uk Ltd | Food product |
| JP5922868B2 (ja) | 2008-07-07 | 2016-05-24 | 持田製薬株式会社 | 脂質異常症の改善または治療薬 |
| EP2320889A4 (en) | 2008-08-15 | 2016-09-21 | Nestec Sa | METHOD FOR INCREASING THE CHANGE OF ENERGY REPLACEMENT |
| CA2736747C (en) | 2008-09-19 | 2018-02-27 | Nestec S.A. | Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| CN102300578A (zh) | 2008-12-01 | 2011-12-28 | 延寿有限责任公司 | 用于改变健康、安康和寿命的方法和组合物 |
| US8562489B2 (en) | 2009-04-26 | 2013-10-22 | Nike, Inc. | Athletic watch |
| BRPI0904259A2 (pt) | 2009-05-06 | 2012-02-28 | Provets-simões Laboratório Ltda | suplemento alimentar para pássaros em fase reprodutiva |
| WO2011003045A1 (en) | 2009-07-01 | 2011-01-06 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
| US8691303B2 (en) | 2009-07-31 | 2014-04-08 | The Iams Company | Dusted animal food |
| US20110064712A1 (en) | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
| CN102630161A (zh) | 2009-09-18 | 2012-08-08 | 珀利弗诺斯自然有限公司 | 通过用岩藻黄质和石榴油酸的组合激活去乙酰化酶Sirtuin来延缓衰老过程的方法 |
| WO2011051974A1 (en) | 2009-10-29 | 2011-05-05 | Nutracryst Therapeutics Private Limited | Metformin and a-amino acids |
| US8173181B2 (en) | 2009-11-09 | 2012-05-08 | Bio-Engineered Supplements & Nutrition, Inc. | Method and composition for improved anabolism |
| WO2011087708A1 (en) | 2010-01-13 | 2011-07-21 | Dodds W Jean | Animal food compositions for promoting liver cleansing and mitigations of intestinal dysbiosis |
| CN102753183A (zh) | 2010-02-03 | 2012-10-24 | 花王株式会社 | 运动功能改善剂 |
| US20110208153A1 (en) | 2010-02-24 | 2011-08-25 | John Alvey | Formulations and methods for nutrient delivery |
| US20120058088A1 (en) | 2010-06-28 | 2012-03-08 | Resveratrol Partners, Llc | Resveratrol-Containing Compositions And Methods Of Use |
| CN102077936B (zh) * | 2010-09-20 | 2013-04-24 | 王强 | 一种糖尿病患者专用的海洋特膳食品 |
| US9167991B2 (en) | 2010-09-30 | 2015-10-27 | Fitbit, Inc. | Portable monitoring devices and methods of operating same |
| WO2012060884A1 (en) | 2010-11-04 | 2012-05-10 | Nestec S.A. | Methods and compositions for preventing and treating osteoarthritis |
| LT2661266T (lt) | 2011-01-07 | 2020-12-10 | Anji Pharma (Us) Llc | Gydimo būdai chemosensorinio receptoriaus ligando pagrindu |
| WO2012097064A1 (en) | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for controlling blood glucose |
| US20120231087A1 (en) | 2011-03-07 | 2012-09-13 | Olympic Seafood | Compositions And Methods for Nutritional Supplementation |
| PH12014500198A1 (en) | 2011-07-15 | 2017-02-10 | Nusirt Sciences Inc | Compositions and methods for modulating metabolic pathways |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| EP2986140A4 (en) | 2013-03-15 | 2016-10-19 | Nusirt Sciences Inc | COMPOSITIONS, PROCESSES AND KIT FOR TREATMENT OF PETS |
| JP2017506651A (ja) | 2014-02-27 | 2017-03-09 | ニューサート サイエンシーズ， インコーポレイテッド | 脂肪肝の低減または予防のための組成物および方法 |
-
2012
- 2012-10-26 US US13/662,345 patent/US9198454B2/en active Active
-
2013
- 2013-03-08 AU AU2013229779A patent/AU2013229779B2/en not_active Ceased
- 2013-03-08 JP JP2014561175A patent/JP6210517B2/ja not_active Expired - Fee Related
- 2013-03-08 CA CA2866718A patent/CA2866718C/en active Active
- 2013-03-08 WO PCT/US2013/030044 patent/WO2013134736A1/en not_active Ceased
- 2013-03-08 HK HK15106559.3A patent/HK1205942A1/xx unknown
- 2013-03-08 EP EP13758140.1A patent/EP2822579B1/en active Active
-
2015
- 2015-10-29 US US14/927,228 patent/US9408410B2/en active Active
-
2016
- 2016-07-08 US US15/206,183 patent/US9713609B2/en active Active
-
2017
- 2017-06-09 US US15/619,374 patent/US9901573B2/en active Active
- 2017-09-06 JP JP2017171209A patent/JP2018012722A/ja active Pending
-
2018
- 2018-02-06 AU AU2018200861A patent/AU2018200861A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510888A5 (enExample) | ||
| Duan et al. | The role of leucine and its metabolites in protein and energy metabolism | |
| McCarty et al. | An increased need for dietary cysteine in support of glutathione synthesis may underlie the increased risk for mortality associated with low protein intake in the elderly | |
| Hashim et al. | Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester | |
| US20200253909A1 (en) | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use | |
| CN1329030C (zh) | 肝癌发生·发展抑制剂 | |
| JP2018012722A5 (enExample) | ||
| US20200375927A1 (en) | R-beta-hydroxybutyrate, s-beta-hydroxybutyrate, and rs-beta-hydroxybutyrate mixed salt compositions | |
| JP5714227B2 (ja) | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 | |
| CN112118855A (zh) | 体重管理组合物 | |
| Cicero et al. | Nutraceuticals and blood pressure control: results from clinical trials and meta-analyses | |
| RU2015143836A (ru) | Лейцин и никотиновая кислота для снижения уровня липидов | |
| AU2020221569B2 (en) | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use | |
| JP2014520864A5 (enExample) | ||
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| ES2492667T3 (es) | Nuevo uso de ácido(s) graso(s) omega-3 | |
| RU2018145067A (ru) | Питательные композиции для защиты сердца у животных-компаньонов | |
| US9238024B2 (en) | Methods for improving health in canines | |
| TW201417806A (zh) | 用於改善兒童的線性生長反應之方法 | |
| Owens | Nutritional support to counteract muscle atrophy | |
| JP2010138170A (ja) | 抗疲労組成物 | |
| TW201417805A (zh) | 用於增加人類生長激素位準之組成物 | |
| US11419836B2 (en) | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions | |
| CN105285634B (zh) | 一种运动训练提效型天然功能饮剂组合物及其应用 | |
| US11337960B2 (en) | Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome |